{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:43:44Z","timestamp":1791924224678,"version":"4.3.4"},"reference-count":119,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,7,16]],"date-time":"2023-07-16T00:00:00Z","timestamp":1689465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,16]],"date-time":"2023-07-16T00:00:00Z","timestamp":1689465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s10147-023-02382-2","type":"journal-article","created":{"date-parts":[[2023,7,16]],"date-time":"2023-07-16T02:01:36Z","timestamp":1689472896000},"page":"1315-1332","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Chapter 3: Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022"],"prefix":"10.1007","volume":"28","author":[{"given":"Yuichi","family":"Ando","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Shimodaira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nao","family":"Takano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiko","family":"Sakaida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koki","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shokichi","family":"Tsukamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keigo","family":"Komine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinari","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taigo","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashige","family":"Kuwabara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Yonezawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimikazu","family":"Yakushijin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Nozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2380-1551","authenticated-orcid":false,"given":"Takeshi","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Hoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoko","family":"Yanagita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Committee of Clinical Practice Guidelines for the Management of Kidney Disease During Anticancer Drug Therapy 2022","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,16]]},"reference":[{"key":"2382_CR1","unstructured":"Yanagita M (2023) Clinical questions and good practice statements in clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022 (manuscript in submission)"},{"key":"2382_CR2","unstructured":"(2021) Nippon Kayaku Co., Ltd. Full prescribing information for Randa\u00ae (in Japanese). https:\/\/mink.nipponkayaku.co.jp\/product\/di\/te_file\/sedi_rani_te.pdf"},{"key":"2382_CR3","unstructured":"(2015) The Japan Lung Cancer Society, and Japanese Society of Medical Oncology, guideline for short hydration method in cisplatin administration, Aug 2015, [Japanese], https:\/\/www.haigan.gr.jp\/uploads\/files\/photos\/1022.pdf"},{"key":"2382_CR4","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/BF00451649","volume":"23","author":"Y Sasaki","year":"1989","unstructured":"Sasaki Y, Tamura T, Eguchi K et al (1989) Pharmacokinetics of (glycolate-0,0\u2019)-diammine platinum(II), a new platinum derivative, in comparison with cisplatin and carboplatin. Cancer Chemother Pharmacol 23:243\u2013246","journal-title":"Cancer Chemother Pharmacol"},{"key":"2382_CR5","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/clpt.2009.139","volume":"86","author":"KK Filipski","year":"2009","unstructured":"Filipski KK, Mathijssen RH, Mikkelsen TS et al (2009) Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther 86:396\u2013402","journal-title":"Clin Pharmacol Ther"},{"key":"2382_CR6","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.3390\/toxins2112490","volume":"2","author":"RP Miller","year":"2010","unstructured":"Miller RP, Tadagavadi RK, Ramesh G et al (2010) Mechanisms of cisplatin nephrotoxicity. Toxins (Basel) 2:2490\u20132518","journal-title":"Toxins (Basel)"},{"key":"2382_CR7","first-page":"632","volume":"9","author":"M Horiuchi","year":"1982","unstructured":"Horiuchi M, Inuyama Y, Kohno N et al (1982) Pharmacokinetics of Cis-dichlorodiammineplatinum (II) [Japanese]. Jpn J Cancer Chemother 9:632\u2013637","journal-title":"Jpn J Cancer Chemother"},{"key":"2382_CR8","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1007\/s004670100610","volume":"16","author":"B Erdlenbruch","year":"2001","unstructured":"Erdlenbruch B, Pekrum A, Roth C et al (2001) Cisplatin nephrotoxicity in children after continuous 72-h and 3x1-h infusions. Pediatr Nephrol 16:586\u2013593","journal-title":"Pediatr Nephrol"},{"key":"2382_CR9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1053\/ctrv.1999.0097","volume":"25","author":"H Lajer","year":"1999","unstructured":"Lajer H, Daugaard G (1999) Cisplatin and hypomagnesemia. Cancer Treat Rev 25:47\u201358","journal-title":"Cancer Treat Rev"},{"key":"2382_CR10","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1007\/s10157-009-0215-1","volume":"13","author":"K Yokoo","year":"2009","unstructured":"Yokoo K, Murakami R, Matsuzaki T et al (2009) Enhanced renal accumulation of cisplatin via renal organic cation transporter deteriorates acute kidney injury in hypomagnesemic rats. Clin Exp Nephrol 13:578\u2013584","journal-title":"Clin Exp Nephrol"},{"key":"2382_CR11","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1016\/j.ejca.2008.08.005","volume":"44","author":"L Bodnar","year":"2008","unstructured":"Bodnar L, Wcislo G, Gasowska-Bodnar A et al (2008) Renal protection with magnesium subcarbonate and magnesium sulphate in patients with epithelial ovarian cancer after cisplatin and paclitaxel chemotherapy: a randomised phase II study. Eur J Cancer 44:2608\u20132614","journal-title":"Eur J Cancer"},{"key":"2382_CR12","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1200\/JCO.2004.00.9720","volume":"24","author":"AC Mita","year":"2006","unstructured":"Mita AC, Sweeney CJ, Baker SD et al (2006) Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol 24:552\u2013562","journal-title":"J Clin Oncol"},{"key":"2382_CR13","doi-asserted-by":"publisher","first-page":"1800884","DOI":"10.1183\/13993003.00884-2018","volume":"52","author":"S Visser","year":"2018","unstructured":"Visser S, Huisbrink J, van\u2019t Veer NE et al (2018) Renal impairment during pemetrexed maintenance in patients with advanced nonsmall cell lung cancer: a cohort study. Eur Respir J 52:1800884","journal-title":"Eur Respir J"},{"key":"2382_CR14","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.lungcan.2020.05.022","volume":"146","author":"N de Rouw","year":"2020","unstructured":"de Rouw N, Boosman RJ, van de Bruinhorst H et al (2020) Cumulative pemetrexed dose increases the risk of nephrotoxicity. Lung Cancer 146:30\u201335","journal-title":"Lung Cancer"},{"key":"2382_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0171066","volume":"12","author":"H Kawazoe","year":"2017","unstructured":"Kawazoe H, Yano A, Ishida Y et al (2017) Non-steroidal anti-inflammatory drugs induce severe hematologic toxicities in lung cancer patients receiving pemetrexed plus carboplatin: A retrospective cohort study. PLoS ONE 12:e0171066","journal-title":"PLoS ONE"},{"key":"2382_CR16","doi-asserted-by":"publisher","first-page":"7824","DOI":"10.1158\/0008-5472.CAN-06-1043","volume":"66","author":"I Nissim","year":"2006","unstructured":"Nissim I, Horyn O, Daikhin Y et al (2006) Ifosfamide-induced nephrotoxicity: mechanism and prevention. Cancer Res 66:7824\u20137831","journal-title":"Cancer Res"},{"key":"2382_CR17","unstructured":"(2022) Shionogi & Co., Ltd. Interview Form for Ifomide\u00ae for Injection (in Japanese): https:\/\/www.shionogi.co.jp\/med\/download.php?h=0a54bf01fc13dae9174a669b0dbf1cee"},{"key":"2382_CR18","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1200\/JCO.1994.12.1.159","volume":"12","author":"R Rossi","year":"1994","unstructured":"Rossi R, G\u00f6dde A, Kleinebrand A et al (1994) Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients. J Clin Oncol 12:159\u2013165","journal-title":"J Clin Oncol"},{"key":"2382_CR19","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1200\/JCO.1991.9.8.1495","volume":"9","author":"CB Pratt","year":"1991","unstructured":"Pratt CB, Meyer WH, Jenkins JJ et al (1991) Ifosfamide, Fanconi\u2019s syndrome, and rickets. J Clin Oncol 9:1495\u20131499","journal-title":"J Clin Oncol"},{"key":"2382_CR20","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1054\/bjoc.2000.1214","volume":"82","author":"R Skinner","year":"2000","unstructured":"Skinner R, Cotterill SJ, Stevens MC (2000) Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children\u2019s Cancer Study Group. Br J Cancer 82:1636\u20131645","journal-title":"Br J Cancer"},{"key":"2382_CR21","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/j.1365-2141.2010.08143.x","volume":"149","author":"MS Cairo","year":"2010","unstructured":"Cairo MS, Coiffier B, Reiter A et al (2010) Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol 149:578\u2013586","journal-title":"Br J Haematol"},{"key":"2382_CR22","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1093\/annonc\/mdv317","volume":"26","author":"M Spina","year":"2015","unstructured":"Spina M, Nagy Z, Ribera JM et al (2015) FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. Ann Oncol 26:2155\u20132161","journal-title":"Ann Oncol"},{"key":"2382_CR23","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1007\/s10147-016-0971-3","volume":"21","author":"K Tamura","year":"2016","unstructured":"Tamura K, Kawai Y, Kiguchi T et al (2016) Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol. Int J Clin Oncol 21:996\u20131003","journal-title":"Int J Clin Oncol"},{"key":"2382_CR24","first-page":"525","volume":"44","author":"I Bellos","year":"2019","unstructured":"Bellos I, Kontzoglou K, Psyrri A et al (2019) Febuxostat administration for the prevention of tumour lysis syndrome: a meta-analysis. J Clin Pharm Ther 44:525\u2013533","journal-title":"J Clin Pharm Ther"},{"key":"2382_CR25","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1053\/j.ajkd.2015.05.017","volume":"66","author":"D Sircar","year":"2015","unstructured":"Sircar D, Chatterjee S, Waikhom R et al (2015) Efficacy of febuxostat for slowing the GFR decline in patients with ckd and asymptomatic hyperuricemia: a 6-month, double-blind, randomized, placebo-controlled trial. Am J Kidney Dis 66:945\u2013950","journal-title":"Am J Kidney Dis"},{"key":"2382_CR26","unstructured":"(2021) Japanese Society of Medical Oncology, Clinical Practice Guidelines for Tumor Lysis Syndrome [Japanese], 2nd edn. Kanehara-Shuppan Co. Ltd, Tokyo"},{"key":"2382_CR27","doi-asserted-by":"publisher","first-page":"4207","DOI":"10.1200\/JCO.2009.26.8896","volume":"28","author":"J Cortes","year":"2010","unstructured":"Cortes J, Moore JO, Maziarz RT et al (2010) Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone\u2014results of a multicenter phase III study. J Clin Oncol 28:4207\u20134213","journal-title":"J Clin Oncol"},{"key":"2382_CR28","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/j.1349-7006.2008.01047.x","volume":"100","author":"K Ishizawa","year":"2009","unstructured":"Ishizawa K, Ogura M, Hamaguchi M et al (2009) Safety and efficacy of rasburicase (SR29142) in a Japanese phase II study. Cancer Sci 100:357\u2013362","journal-title":"Cancer Sci"},{"key":"2382_CR29","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s40264-014-0255-7","volume":"38","author":"KC Allen","year":"2015","unstructured":"Allen KC, Champlain AH, Cotliar JA et al (2015) Risk of anaphylaxis with repeated courses of rasburicase: a research on adverse drug events and reports (RADAR) project. Drug Saf 38:183\u2013187","journal-title":"Drug Saf"},{"key":"2382_CR30","first-page":"62","volume":"58","author":"S Kagami","year":"2015","unstructured":"Kagami S (2015) Clinical practice of Guidelines for atypical Hemolytic Uremic Syndrome (sHUS) 2015 [Japanese]. Jpns J Nephrol 58:62\u201375","journal-title":"Jpns J Nephrol"},{"key":"2382_CR31","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/jca.21705","volume":"34","author":"A Padmanabhan","year":"2019","unstructured":"Padmanabhan A, Connelly-Smith L, Aqui N et al (2019) Guidelines on the Use of Therapeutic Apheresis in Clinical practice\u2014evidence-based approach from the Writing Committee of the American Society for apheresis: the eighth special issue. J Clin Apher 34:171\u2013354","journal-title":"J Clin Apher"},{"key":"2382_CR32","doi-asserted-by":"publisher","first-page":"130","DOI":"10.5414\/CNP71130","volume":"71","author":"I Glezerman","year":"2009","unstructured":"Glezerman I, Kris MG, Miller V et al (2009) Gemcitabine nephrotoxicity and hemolytic uremic syndrome: report of 29 cases from a single institution. Clin Nephrol 71:130\u2013139","journal-title":"Clin Nephrol"},{"key":"2382_CR33","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1634\/theoncologist.11-6-694","volume":"11","author":"BC Widemann","year":"2006","unstructured":"Widemann BC, Adamson PC (2006) Understanding and managing methotrexate nephrotoxicity. Oncologist 11:694\u2013703","journal-title":"Oncologist"},{"key":"2382_CR34","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s00280-010-1259-3","volume":"66","author":"O Mir","year":"2010","unstructured":"Mir O, Ropert S, Babinet A et al (2010) Hyper-alkalinization without hyper-hydration for the prevention of high-dose methotrexate acute nephrotoxicity in patients with osteosarcoma. Cancer Chemother Pharmacol 66:1059\u20131063","journal-title":"Cancer Chemother Pharmacol"},{"key":"2382_CR35","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1634\/theoncologist.2017-0243","volume":"23","author":"LB Ramsey","year":"2018","unstructured":"Ramsey LB, Balis FM, O\u2019Brien MM et al (2018) Consensus guideline for use of glucarpidase in patients with high-dose methotrexate induced acute kidney injury and delayed methotrexate clearance. Oncologist 23:52\u201361","journal-title":"Oncologist"},{"key":"2382_CR36","unstructured":"(2022) Ohara Pharmaceutical Co., Ltd. Interview form for Glucarpidase (Genetical Recombination) \u201cMegludase\u00ae for Intravenous Use 1000\u201d [Japanese] https:\/\/www.ohara-ch.co.jp\/appendix\/pdf\/inc07\/megludase-IF.pdf"},{"key":"2382_CR37","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1093\/annonc\/mdv136","volume":"26","author":"V Launay-Vacher","year":"2015","unstructured":"Launay-Vacher V, Aapro M, De Castro Jr. G et al (2015) Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN). Ann Oncol 26:1677\u20131684","journal-title":"Ann Oncol"},{"key":"2382_CR38","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-023-02372-4","author":"S Muto","year":"2023","unstructured":"Muto S (2023) Chapter 1: Evaluation of kidney function in patients undergoing anticancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy. Int J Clin Oncol. https:\/\/doi.org\/10.1007\/s10147-023-02372-4","journal-title":"Int J Clin Oncol"},{"key":"2382_CR39","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.ejca.2009.11.001","volume":"46","author":"H Izzedine","year":"2010","unstructured":"Izzedine H, Massard C, Spano JP et al (2010) VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management. Eur J Cancer 46:439\u2013448","journal-title":"Eur J Cancer"},{"key":"2382_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0090135","volume":"9","author":"ZF Zhang","year":"2014","unstructured":"Zhang ZF, Wang T, Liu LH et al (2014) Risks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta-analysis. PLoS ONE 9:e90135","journal-title":"PLoS ONE"},{"key":"2382_CR41","unstructured":"(2022) Japan Clinical Oncology Group, Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 [Japanese], http:\/\/www.jcog.jp\/doctor\/tool\/CTCAEv5J_20220901_version.pdf"},{"key":"2382_CR42","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1681\/ASN.2010020167","volume":"21","author":"S Wu","year":"2010","unstructured":"Wu S, Kim C, Baer L et al (2010) Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol 21:1381\u20131389","journal-title":"J Am Soc Nephrol"},{"key":"2382_CR43","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1053\/j.ajkd.2006.11.039","volume":"49","author":"X Zhu","year":"2007","unstructured":"Zhu X, Wu S, Dahut WL et al (2007) Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 49:186\u2013193","journal-title":"Am J Kidney Dis"},{"key":"2382_CR44","first-page":"460","volume":"29","author":"S Wu","year":"2011","unstructured":"Wu S, Keresztes RS (2011) Antiangiogenic agents for the treatment of nonsmall cell lung cancer: characterizing the molecular basis for serious adverse events. Cancer Investig 29:460\u2013471","journal-title":"Cancer Investig"},{"key":"2382_CR45","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","volume":"358","author":"V Eremina","year":"2008","unstructured":"Eremina V, Jefferson JA, Kowalewska J et al (2008) VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358:1129\u20131136","journal-title":"N Engl J Med"},{"key":"2382_CR46","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1200\/JCO.2004.11.022","volume":"22","author":"DH Johnson","year":"2004","unstructured":"Johnson DH, Fehrenbacher L, Novotny WF et al (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22:2184\u20132191","journal-title":"J Clin Oncol"},{"key":"2382_CR47","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1172\/JCI17189","volume":"111","author":"SE Maynard","year":"2003","unstructured":"Maynard SE, Min JY, Merchan J et al (2003) Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Investig 111:649\u2013658","journal-title":"J Clin Investig"},{"key":"2382_CR48","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1093\/ndt\/gfn657","volume":"24","author":"G Boll\u00e9e","year":"2009","unstructured":"Boll\u00e9e G, Patey N, Cazajous G et al (2009) Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. Nephrol Dial Transplant 24:682\u2013685","journal-title":"Nephrol Dial Transplant"},{"key":"2382_CR49","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1053\/j.ajkd.2006.11.024","volume":"49","author":"BA George","year":"2007","unstructured":"George BA, Zhou XJ, Toto R (2007) Nephrotic syndrome after bevacizumab: case report and literature review. Am J Kidney Dis 49:e23-29","journal-title":"Am J Kidney Dis"},{"key":"2382_CR50","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1093\/annonc\/mdp472","volume":"21","author":"EN Overkleeft","year":"2010","unstructured":"Overkleeft EN, Goldschmeding R, van Reekum F et al (2010) Nephrotic syndrome caused by the angiogenesis inhibitor sorafenib. Ann Oncol 21:184\u2013185","journal-title":"Ann Oncol"},{"key":"2382_CR51","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1093\/ndt\/gfp666","volume":"25","author":"O Costero","year":"2010","unstructured":"Costero O, Picazo ML, Zamora P et al (2010) Inhibition of tyrosine kinases by sunitinib associated with focal segmental glomerulosclerosis lesion in addition to thrombotic microangiopathy. Nephrol Dial Transplant 25:1001\u20131003","journal-title":"Nephrol Dial Transplant"},{"key":"2382_CR52","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1097\/PAP.0000000000000122","volume":"23","author":"ML Troxell","year":"2016","unstructured":"Troxell ML, Higgins JP, Kambham N (2016) Antineoplastic treatment and renal injury: an update on renal pathology due to cytotoxic and targeted therapies. Adv Anat Pathol 23:310\u2013329","journal-title":"Adv Anat Pathol"},{"key":"2382_CR53","unstructured":"(2022) AVASTIN\u00ae (bevacizumab) package insert, Chugai Pharmaceutical Co., Ltd. 4th edition (June, 2022). https:\/\/chugai-pharm.jp\/content\/dam\/chugai\/product\/ava\/div\/pi\/doc\/ava_pi.pdf"},{"key":"2382_CR54","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1345\/aph.1M670","volume":"44","author":"J Yeh","year":"2010","unstructured":"Yeh J, Frieze D, Martins R et al (2010) Clinical utility of routine proteinuria evaluation in treatment decisions of patients receiving bevacizumab for metastatic solid tumors. Ann Pharmacother 44:1010\u20131015","journal-title":"Ann Pharmacother"},{"key":"2382_CR55","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/S2468-1253(21)00313-7","volume":"6","author":"RH Xu","year":"2021","unstructured":"Xu RH, Zhang Y, Pan H et al (2021) Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol 6:1015\u20131024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2382_CR56","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S et al (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391:1163\u20131173","journal-title":"Lancet"},{"key":"2382_CR57","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1093\/jnci\/djm311","volume":"100","author":"TV Patel","year":"2008","unstructured":"Patel TV, Morgan JA, Demetri GD et al (2008) A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. J Natl Cancer Inst 100:282\u2013284","journal-title":"J Natl Cancer Inst"},{"key":"2382_CR58","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1159\/000364782","volume":"40","author":"N Leeaphorn","year":"2014","unstructured":"Leeaphorn N, Kue APP, Thamcharoen N et al (2014) Prevalence of cancer in membranous nephropathy: a systematic review and meta-analysis of observational studies. Am J Nephrol 40:29\u201335","journal-title":"Am J Nephrol"},{"key":"2382_CR59","doi-asserted-by":"publisher","first-page":"51492","DOI":"10.18632\/oncotarget.18190","volume":"8","author":"T Zhao","year":"2017","unstructured":"Zhao T, Wang X, Xu T et al (2017) Bevacizumab significantly increases the risks of hypertension and proteinuria in cancer patients: a systematic review and comprehensive meta-analysis. Oncotarget 8:51492\u201351506","journal-title":"Oncotarget"},{"key":"2382_CR60","first-page":"1145","volume":"48","author":"S Yamaguchi","year":"2021","unstructured":"Yamaguchi S, Murayama R, Satoh E et al (2021) Effects of tyrosine kinase inhibitors on blood pressure in patients with unresectable or advanced recurrent renal cell carcinoma-bayes-mixed treatment comparison meta-analysis. Gan To Kagaku Ryoho 48:1145\u20131151","journal-title":"Gan To Kagaku Ryoho"},{"key":"2382_CR61","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.jacc.2009.02.050","volume":"53","author":"ET Yeh","year":"2009","unstructured":"Yeh ET, Bickford CL (2009) Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 53:2231\u20132247","journal-title":"J Am Coll Cardiol"},{"key":"2382_CR62","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1093\/jnci\/djr128","volume":"103","author":"BI Rini","year":"2011","unstructured":"Rini BI, Cohen DP, Lu DR et al (2011) Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 103:763\u2013773","journal-title":"J Natl Cancer Inst"},{"key":"2382_CR63","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","volume":"37","author":"JL Zamorano","year":"2016","unstructured":"Zamorano JL, Lancellotti P, Rodriguez Mu\u00f1oz D et al (2016) 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37:2768\u20132801","journal-title":"Eur Heart J"},{"key":"2382_CR64","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.pharmthera.2017.08.012","volume":"182","author":"M Li","year":"2018","unstructured":"Li M, Kroetz DL (2018) Bevacizumab-induced hypertension: clinical presentation and molecular understanding. Pharmacol Ther 182:152\u2013160","journal-title":"Pharmacol Ther"},{"key":"2382_CR65","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.cjca.2015.12.023","volume":"32","author":"AC Cameron","year":"2016","unstructured":"Cameron AC, Touyz RM, Lang NN (2016) Vascular complications of cancer chemotherapy. Can J Cardiol 32:852\u2013862","journal-title":"Can J Cardiol"},{"key":"2382_CR66","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1093\/annonc\/mdn713","volume":"20","author":"H Izzedine","year":"2009","unstructured":"Izzedine H, Ederhy S, Goldwasser F et al (2009) Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 20:807\u2013815","journal-title":"Ann Oncol"},{"key":"2382_CR67","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1681\/ASN.2018080853","volume":"30","author":"CC Estrada","year":"2019","unstructured":"Estrada CC, Maldonado A, Mallipattu SK (2019) Therapeutic inhibition of VEGF signaling and associated nephrotoxicities. J Am Soc Nephrol 30:187\u2013200","journal-title":"J Am Soc Nephrol"},{"key":"2382_CR68","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1188\/13.CJON.425-433","volume":"17","author":"NN Grenon","year":"2013","unstructured":"Grenon NN (2013) Managing toxicities associated with antiangiogenic biologic agents in combination with chemotherapy for metastatic colorectal cancer. Clin J Oncol Nurs 17:425\u2013433","journal-title":"Clin J Oncol Nurs"},{"key":"2382_CR69","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1517\/17425255.2012.656845","volume":"8","author":"L Horsley","year":"2012","unstructured":"Horsley L, Marti K, Jayson GC (2012) Is the toxicity of anti-angiogenic drugs predictive of outcome? A review of hypertension and proteinuria as biomarkers of response to anti-angiogenic therapy. Expert Opin Drug Metab Toxicol 8:283\u2013293","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2382_CR70","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1038\/bjc.2016.147","volume":"114","author":"MJ Sorich","year":"2016","unstructured":"Sorich MJ, Rowland A, Kichenadasse G et al (2016) Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data. Br J Cancer 114:1313\u20131317","journal-title":"Br J Cancer"},{"key":"2382_CR71","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3904\/kjim.2014.29.1.40","volume":"29","author":"SH Baek","year":"2014","unstructured":"Baek SH, Kim H, Lee J et al (2014) Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea. Korean J Intern Med 29:40\u201348","journal-title":"Korean J Intern Med"},{"key":"2382_CR72","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0116527","volume":"10","author":"J Feliu","year":"2015","unstructured":"Feliu J, Salud A, Safont MJ et al (2015) Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer. PLoS ONE 10:e0116527","journal-title":"PLoS ONE"},{"key":"2382_CR73","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1053\/j.ajkd.2015.02.340","volume":"66","author":"H Izzedine","year":"2015","unstructured":"Izzedine H, Perazella MA (2015) Thrombotic microangiopathy, cancer, and cancer drugs. Am J Kidney Dis 66:857\u2013868","journal-title":"Am J Kidney Dis"},{"key":"2382_CR74","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/ki.2013.344","volume":"85","author":"H Izzedine","year":"2014","unstructured":"Izzedine H, Mangier M, Ory V et al (2014) Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy. Kidney Int 85:457\u2013470","journal-title":"Kidney Int"},{"key":"2382_CR75","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/MD.0000000000000207","volume":"93","author":"H Izzedine","year":"2014","unstructured":"Izzedine H, Escudier B, Lhomme C et al (2014) Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center. Medicine (Baltimore) 93:333\u2013339","journal-title":"Medicine (Baltimore)"},{"key":"2382_CR76","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1172\/JCI108035","volume":"55","author":"R Gugler","year":"1975","unstructured":"Gugler R, Shoeman DW, Huffman DH et al (1975) Pharmacokinetics of drugs in patients with the nephrotic syndrome. J Clin Investig 55:1182\u20131189","journal-title":"J Clin Investig"},{"key":"2382_CR77","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1007\/s00277-016-2795-7","volume":"95","author":"SN Reiss","year":"2016","unstructured":"Reiss SN, Buie LW, Adel N et al (2016) Hypoalbuminemia is significantly associated with increased clearance time of high dose methotrexate in patients being treated for lymphoma or leukemia. Ann Hematol 95:2009\u20132015","journal-title":"Ann Hematol"},{"key":"2382_CR78","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1471-2407-10-50","volume":"10","author":"O Arrieta","year":"2010","unstructured":"Arrieta O, Michel Ortega RM, Villanueva-Rodr\u00edguez G et al (2010) Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study. BMC Cancer 10:50","journal-title":"BMC Cancer"},{"key":"2382_CR79","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1177\/1060028020942485","volume":"55","author":"JL Murdock","year":"2021","unstructured":"Murdock JL, Duco MR, Reeves DJ (2021) Tolerability of highly protein bound targeted oral oncolytic drugs in patients with hypoalbuminemia: a retrospective analysis. Ann Pharmacother 55:165\u2013173","journal-title":"Ann Pharmacother"},{"key":"2382_CR80","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28065","volume":"67","author":"TW McLean","year":"2020","unstructured":"McLean TW, Stewart RM, Curley TP et al (2020) Hypoalbuminemia in children with cancer treated with chemotherapy. Pediatr Blood Cancer 67:e28065","journal-title":"Pediatr Blood Cancer"},{"key":"2382_CR81","doi-asserted-by":"publisher","first-page":"478","DOI":"10.3109\/s10165-009-0195-8","volume":"19","author":"T Takeuchi","year":"2009","unstructured":"Takeuchi T, Miyasaka N, Inoue K et al (2009) Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study. Mod Rheumatol 19:478\u2013487","journal-title":"Mod Rheumatol"},{"key":"2382_CR82","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1182\/blood-2016-10-744292","volume":"129","author":"M Tout","year":"2017","unstructured":"Tout M, Casasnovas O, Meignan M et al (2017) Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report. Blood 129:2616\u20132623","journal-title":"Blood"},{"key":"2382_CR83","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1158\/1535-7163.MCT-16-0895","volume":"16","author":"J Tabernero","year":"2017","unstructured":"Tabernero J, Ohtsu A, Muro K et al (2017) Exposure-response analyses of ramucirumab from two randomized, phase III trials of second-line treatment for advanced gastric or gastroesophageal junction cancer. Mol Cancer Ther 16:2215\u20132222","journal-title":"Mol Cancer Ther"},{"key":"2382_CR84","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1177\/1060028018803587","volume":"53","author":"U Fogueri","year":"2019","unstructured":"Fogueri U, Cheungapasitporn W, Bourne D et al (2019) Rituximab exhibits altered pharmacokinetics in patients with membranous nephropathy. Ann Pharmacother 53:357\u2013363","journal-title":"Ann Pharmacother"},{"key":"2382_CR85","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1007\/s00467-015-3120-8","volume":"30","author":"CE Counsilman","year":"2015","unstructured":"Counsilman CE, Jol-van der Zijde CM, Stevens J et al (2015) Pharmacokinetics of rituximab in a pediatric patient with therapy-resistant nephrotic syndrome. Pediatr Nephrol 30:1367\u20131370","journal-title":"Pediatr Nephrol"},{"key":"2382_CR86","first-page":"1372859","volume":"2017","author":"K Stahl","year":"2017","unstructured":"Stahl K, Duong M, Schwarz A et al (2017) Kinetics of rituximab excretion into urine and peritoneal fluid in two patients with nephrotic syndrome. Case Rep Nephrol 2017:1372859","journal-title":"Case Rep Nephrol"},{"key":"2382_CR87","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s11095-019-2624-5","volume":"36","author":"A Yonezawa","year":"2019","unstructured":"Yonezawa A, Otani Y, Kitano T et al (2019) Concentration and glycoform of rituximab in plasma of patients with b cell non-Hodgkin\u2019s lymphoma. Pharm Res 36:82","journal-title":"Pharm Res"},{"key":"2382_CR88","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1093\/ndt\/gfaa137","volume":"36","author":"C Stein","year":"2021","unstructured":"Stein C, Burtey S, Mancini J et al (2021) Acute kidney injury in patients treated with anti-programmed death receptor-1 for advanced melanoma: a real-life study in a single-centre cohort. Nephrol Dial Transplant 36:1664\u20131674","journal-title":"Nephrol Dial Transplant"},{"key":"2382_CR89","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.2215\/CJN.00990119","volume":"14","author":"H Seethapathy","year":"2019","unstructured":"Seethapathy H, Zhao S, Chute DF et al (2019) The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors. Clin J Am Soc Nephrol 14:1692\u20131700","journal-title":"Clin J Am Soc Nephrol"},{"key":"2382_CR90","doi-asserted-by":"publisher","first-page":"e000467","DOI":"10.1136\/jitc-2019-000467","volume":"8","author":"A Meraz-Mu\u00f1oz","year":"2020","unstructured":"Meraz-Mu\u00f1oz A, Amir E, Ng P et al (2020) Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes. J Immunother Cancer 8:e000467","journal-title":"J Immunother Cancer"},{"key":"2382_CR91","first-page":"887","volume":"37","author":"C Garc\u00eda-Carro","year":"2022","unstructured":"Garc\u00eda-Carro C, Bolufer M, Bury R et al (2022) Acute kidney injury as a risk factor for mortality in oncological patients receiving checkpoint inhibitors. Nephrol Dial Transplant 37:887\u2013894","journal-title":"Nephrol Dial Transplant"},{"key":"2382_CR92","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1053\/j.ajkd.2017.04.026","volume":"70","author":"A Kitchlu","year":"2017","unstructured":"Kitchlu A, Fingrut W, Avila-Casado C et al (2017) Nephrotic syndrome with cancer immunotherapies: a report of 2 cases. Am J Kidney Dis 70:581\u2013585","journal-title":"Am J Kidney Dis"},{"key":"2382_CR93","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1111\/1759-7714.13405","volume":"11","author":"K Zheng","year":"2020","unstructured":"Zheng K, Qiu W, Wang H et al (2020) Clinical recommendations on diagnosis and treatment of immune checkpoint inhibitor-induced renal immune-related adverse events. Thorac Cancer 11:1746\u20131751","journal-title":"Thorac Cancer"},{"key":"2382_CR94","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","volume":"90","author":"FB Cortazar","year":"2016","unstructured":"Cortazar FB, Marrone KA, Troxell ML et al (2016) Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int 90:638\u2013647","journal-title":"Kidney Int"},{"key":"2382_CR95","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1681\/ASN.2019070676","volume":"31","author":"FB Cortazar","year":"2020","unstructured":"Cortazar FB, Kibbelaar ZA, Glezerman IG et al (2020) Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study. J Am Soc Nephrol 31:435\u2013446","journal-title":"J Am Soc Nephrol"},{"key":"2382_CR96","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1681\/ASN.2018050488","volume":"29","author":"MA Perazella","year":"2018","unstructured":"Perazella MA, Shirali AC (2018) Nephrotoxicity of cancer immunotherapies: past, present and future. J Am Soc Nephrol 29:2039\u20132052","journal-title":"J Am Soc Nephrol"},{"key":"2382_CR97","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.kint.2019.07.022","volume":"97","author":"MA Perazella","year":"2020","unstructured":"Perazella MA, Shirali AC (2020) Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do? Kidney Int 97:62\u201374","journal-title":"Kidney Int"},{"key":"2382_CR98","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/s41581-018-0035-1","volume":"14","author":"K Sury","year":"2018","unstructured":"Sury K, Perazella MA, Shirali AC (2018) Cardiorenal complications of immune checkpoint inhibitors. Nat Rev Nephrol 14:571\u2013588","journal-title":"Nat Rev Nephrol"},{"key":"2382_CR99","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.ekir.2019.06.001","volume":"4","author":"C Cassol","year":"2019","unstructured":"Cassol C, Satoskar A, Lozanski G et al (2019) Anti-PD-1 immunotherapy may induce interstitial nephritis with increased tubular epithelial expression of PD-L1. Kidney Int Rep 4:1152\u20131160","journal-title":"Kidney Int Rep"},{"key":"2382_CR100","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMc0904283","volume":"361","author":"F Fadel","year":"2009","unstructured":"Fadel F, El Karoui K, Knebelmann B (2009) Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med 361:211\u2013212","journal-title":"N Engl J Med"},{"key":"2382_CR101","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40425-018-0478-8","volume":"7","author":"O Mamlouk","year":"2019","unstructured":"Mamlouk O, Selamet U, Machado S et al (2019) Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience. J Immunother Cancer 7:2","journal-title":"J Immunother Cancer"},{"key":"2382_CR102","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.2169\/internalmedicine.9814-17","volume":"57","author":"S Kishi","year":"2018","unstructured":"Kishi S, Minato M, Saijo A et al (2018) IgA nephropathy after nivolumab therapy for postoperative recurrence of lung squamous cell carcinoma. Intern Med 57:1259\u20131263","journal-title":"Intern Med"},{"key":"2382_CR103","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/pin.12918","volume":"70","author":"H Mo","year":"2020","unstructured":"Mo H, Yau D, Mirshahidi H et al (2020) AA amyloidosis associated with pulmonary squamous cell carcinoma treated with chemoradiation and immune checkpoint inhibitor therapy. Pathol Int 70:303\u2013305","journal-title":"Pathol Int"},{"key":"2382_CR104","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ekir.2020.10.002","volume":"6","author":"A Kitchlu","year":"2021","unstructured":"Kitchlu A, Jhaveri KD, Wadhwani S et al (2021) A systematic review of immune checkpoint inhibitor-associated glomerular disease. Kidney Int Rep 6:66\u201377","journal-title":"Kidney Int Rep"},{"key":"2382_CR105","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ejca.2021.01.005","volume":"147","author":"M Espi","year":"2021","unstructured":"Espi M, Teuma C, Novel-Catin E et al (2021) Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study. Eur J Cancer 147:29\u201339","journal-title":"Eur J Cancer"},{"key":"2382_CR106","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1159\/000455014","volume":"45","author":"R Wanchoo","year":"2017","unstructured":"Wanchoo R, Karam S, Uppal NN et al (2017) Adverse renal effects of immune checkpoint inhibitors: a narrative review. Am J Nephrol 45:160\u2013169","journal-title":"Am J Nephrol"},{"key":"2382_CR107","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1634\/theoncologist.2018-0764","volume":"24","author":"ME Sise","year":"2019","unstructured":"Sise ME, Seethapathy H, Reynolds KL (2019) Diagnosis and management of immune checkpoint inhibitor-associated renal toxicity: illustrative case and review. Oncologist 24:735\u2013742","journal-title":"Oncologist"},{"key":"2382_CR108","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","volume":"11","author":"C Robert","year":"2020","unstructured":"Robert C (2020) A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun 11:3801","journal-title":"Nat Commun"},{"key":"2382_CR109","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1007\/s10637-020-01039-5","volume":"39","author":"H Li","year":"2021","unstructured":"Li H, Xu J, Bai Y et al (2021) Nephrotoxicity in patients with solid tumors treated with anti-PD-1\/PD-L1 monoclonal antibodies: a systematic review and meta-analysis. Investig New Drugs 39:860\u2013870","journal-title":"Investig New Drugs"},{"key":"2382_CR110","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.2215\/CJN.02340219","volume":"14","author":"MA Perazella","year":"2019","unstructured":"Perazella MA, Sprangers B (2019) AKI in patients receiving immune checkpoint inhibitors. Clin J Am Soc Nephrol 14:1077\u20131079","journal-title":"Clin J Am Soc Nephrol"},{"key":"2382_CR111","doi-asserted-by":"publisher","first-page":"130","DOI":"10.34067\/KID.0000852019","volume":"1","author":"S Gupta","year":"2020","unstructured":"Gupta S, Cortazar FB, Riella LV et al (2020) Immune checkpoint inhibitor nephrotoxicity: update 2020. Kidney360 1:130\u2013140","journal-title":"Kidney360"},{"key":"2382_CR112","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s10157-020-01986-6","volume":"25","author":"Y Ubara","year":"2021","unstructured":"Ubara Y, Kawaguchi T, Nagasawa T et al (2021) Kidney biopsy guidebook 2020 in Japan. Clin Exp Nephrol 25:325\u2013364","journal-title":"Clin Exp Nephrol"},{"key":"2382_CR113","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD et al (2021) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol 39:4073\u20134126","journal-title":"J Clin Oncol"},{"key":"2382_CR114","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","volume":"33","author":"TZ Horvat","year":"2015","unstructured":"Horvat TZ, Adel NG, Dang TO et al (2015) Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol 33:3193\u20133198","journal-title":"J Clin Oncol"},{"key":"2382_CR115","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.1200\/JCO.2017.73.2289","volume":"35","author":"D Schadendorf","year":"2017","unstructured":"Schadendorf D, Wolchok JD, Hodi FS et al (2017) Efficacy and Safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials. J Clin Oncol 35:3807\u20133814","journal-title":"J Clin Oncol"},{"key":"2382_CR116","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378:158\u2013168","journal-title":"N Engl J Med"},{"key":"2382_CR117","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1093\/ckj\/sfaa008","volume":"14","author":"D Oleas","year":"2021","unstructured":"Oleas D, Bolufer M, Agraz I et al (2021) Acute interstitial nephritis associated with immune checkpoint inhibitors: a single-centre experience. Clin Kidney J 14:1364\u20131370","journal-title":"Clin Kidney J"},{"key":"2382_CR118","volume":"3","author":"A Osa","year":"2018","unstructured":"Osa A et al (2018) Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients. JCI. Insight. 3:e59125","journal-title":"Insight."},{"key":"2382_CR119","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1177\/2399369320907598","volume":"4","author":"S Lapman","year":"2020","unstructured":"Lapman S, Whittier WL, Parikh R et al (2020) Immune checkpoint inhibitor-associated renal amyloid A amyloidosis: a case series and review of the literature. J Onco-Nephrol 4:52\u201358","journal-title":"J Onco-Nephrol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-023-02382-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-023-02382-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-023-02382-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T05:09:18Z","timestamp":1695964158000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-023-02382-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,16]]},"references-count":119,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["2382"],"URL":"https:\/\/doi.org\/10.1007\/s10147-023-02382-2","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,16]]},"assertion":[{"value":"22 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Y.A has received honoraria from Chugai Pharmaceutical Co., Ltd., Bayer Holding Ltd., and research funding from Chugai Pharmaceutical Co., Ltd., Geo Holdings Corporation, and BeiGene, Ltd. H.N has received honoraria from MSD K.K., Astellas pharma Inc., and Merck Biopharma Co., Ltd., research fundings from Chugai Pharmaceutical Co. Ltd., and a scholarship donation from Bayer AG. E.S has received honoraria from Pfizer Japan Inc., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Novartis Pharmaceuticals Corporation, and Janssen Pharmaceutical K.K. K.M has received honoraria from MSD, Kyowa Kirin Co., Ltd., and Chugai-Pharmaceutical Co., Ltd., and research fundings from DAIICHI SANKYO COMPANY, MSD, Eli Lilly Japan K.K, Gilead Sciences, and Eisai Co., Ltd. Y.F has received honoraria from AstraZeneca, Bristol-Myers Squibb Company, Chugai-Pharmaceutical Co., Ltd., DAIICHI SANKYO COMPANY, Micron, MSD, and ONO PHARMACEUTICAL CO., LTD., and research fundings from Abbvie, Amgen, AnHeart, AstraZeneca, Bristol-Myers Squibb Company, Chugai-Pharmaceutical Co., Ltd., Eli Lilly Japan K.K, Incyte, and MSD. T.K has received honoraria from Chugai, AstraZeneca and Sysmex, and research funding from PACT Pharma, Chugai, Daiichi-Sankyo, Novartis, Eli Lilly, Pfizer, Janssen Pharmaceutical K.K., Zymworks, and Takeda Pharmaceutical Company Limited. H.K has received honoraria from Astellas Pharma Inc, Takeda Pharmaceutical Company Limited, Bayer AG, and Janssen Pharmaceutical K.K., and scholarship donations from Takeda Pharmaceutical Company Limited and Bayer AG. T. K received honoraria from AstraZeneca. J.H has received honoraria from Kyowa Kirin Co., Ltd., Mitsubishi Tanabe Pharma, Ono Pharm, AstraZeneca and Astellas Pharma Inc, and a research grant from Otsuka Pharmaceutical Co., Ltd. M. Yanagita has received honoraria from Astellas Pharma Inc, AstraZeneca, Kyowa Kirin Co., Ltd., Chugai-Pharmaceutical Co., Ltd., Bayer AG, and Mitsubishi Tanabe Pharma, and research grants from Mitsubishi Tanabe Pharma, Boehringer Ingelheim International GmbH, and scholarship donations from Kyowa Kirin Co., Ltd., Chugai-Pharmaceutical Co., Ltd., and Mitsubishi Tanabe Pharma. The other authors declare no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}